ArticleFrontiers in public health2025
Global, regional, and national burden of gastroesophageal reflux disease (1990-2021): age-period-cohort analysis and Bayesian projections.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and risk factors of gastro-oesophageal reflux disease in Saudi Arabia: a systematic review and meta-analysis.BMJ open · 2026Pooled it
- Formulation and optimization of gastroretentive tablets containing famotidine in combination with antacids: In vitro evaluations and stability studies.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Gastroesophageal reflux disease and childhood asthma: A bidirectional two-sample Mendelian randomization study.Medicine · 2026Article
- Genetic evidence links alcohol, coffee, cheese, and anxiety to GERD risk: A Mendelian randomization study.Medicine · 2026Article
- The impact of gastroesophageal reflux disease in East Asia and China between 1990 and 2021: insights from the 2021 global burden of disease research.BMC gastroenterology · 2026Article
- The pathogenesis and surgical treatment progress of gastroesophageal reflux disease.Frontiers in surgery · 2026Review
- FODMAP intake, gut microbiota, and gastroesophageal reflux disease: a triangulated study of Mendelian randomization and clinical validation.Frontiers in nutrition · 2026Article
- Ecological co-burden patterns of GERD and asthma: a multi-method analysis of representative global regions.Frontiers in nutrition · 2026Article
- Burden of gastroesophageal reflux disease among women of childbearing age, with projections to 2050: an analysis of the Global Burden of Disease study 2021.Frontiers in global women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastroesophageal reflux disease (GERD) is a common chronic upper gastrointestinal disorder that causes discomfort and increases the risk of esophageal adenocarcinoma. The global burden of GERD has steadily increased, establishing it as a critical public health issue. This study systematically evaluated the global, regional, and national burden of GERD from 1990 to 2021, revealing epidemiological trends and regional disparities to inform targeted intervention strategies. Methods: We utilized data from the 2021 Global Burden of Disease Study (GBD) to assess the prevalence, incidence, and years lived with disability (YLDs) of GERD. Key indicators included age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), age-standardized YLDs rate (ASYR), and estimated annual percentage change (EAPC). Analyses were stratified by age, gender, and socio-demographic index (SDI). Age-period-cohort (APC) models were applied to examine trends in the 15-49 age group, and Bayesian APC models were used to project future trends. Results: In 2021, global GERD prevalence reached 825.6 million (95% uncertainty interval: 732.99-925.56 million). From 1990 to 2021, incident cases, prevalent cases, and YLDs rose by 83.16, 80.06, and 82.46%, respectively. The ASIR, ASPR, and ASYR all showed upward trends, with EAPCs of 0.097, 0.076, and 0.083. The highest burden of ASIR, ASPR, and ASYR was observed in Tropical Latin America in 2021, while the lowest was in East Asia. Regions with lower SDI had higher ASIR, ASPR, and ASYR. In the 15-49 age group, the GERD burden increased with age across all SDI regions, with unfavorable period effects observed in high and high-middle SDI regions, as well as adverse cohort effects in high-middle and middle SDI regions. Projections indicate that by 2035, global GERD cases in this age group will reach 527.2 million (ASPR: 12,082.06/100,000), with 214.6 million incident cases (ASIR: 4,916.68/100,000) and 4.1 million YLDs (ASYR: 94.47/100,000). Conclusion: GERD poses a growing global health challenge. Insights from these observed epidemiological patterns can assist policymakers in developing targeted measures to reduce its impact, particularly in high-risk regions and younger demographics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.